Slingshot members are tracking this event:
Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jul 26, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Vk0214, In Vivo Model, X-linked Adrenoleukodystrophy, X-ald, Lower Plasma Vlcfa Levels, Thyroid Beta Receptor, Abcd1 Transporter, Vlcfa Metabolism, Adrenoleukodystrophy